SAVA - Cassava Sciences, Inc. Stock Price and Quote

SAVA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.90	Insider Own	2.70%	Shs Outstand	40.78M	Perf Week	-7.00%
Market Cap	998.43M	Forward P/E	-	EPS next Y	-2.77	Insider Trans	8.64%	Shs Float	39.45M	Perf Month	-3.51%
Income	-76.20M	PEG	-	EPS next Q	-0.56	Inst Own	25.50%	Short Float / Ratio	26.51% / 8.07	Perf Quarter	-24.53%
Sales	-	P/S	-	EPS this Y	-130.80%	Inst Trans	5.38%	Short Interest	10.46M	Perf Half Y	-47.09%
Book/sh	5.58	P/B	4.33	EPS next Y	25.60%	ROA	-33.40%	Target Price	84.00	Perf Year	-40.48%
Cash/sh	4.86	P/C	4.97	EPS next 5Y	-	ROE	-34.60%	52W Range	13.84 - 51.59	Perf YTD	-19.06%
Dividend	-	P/FCF	-	EPS past 5Y	-0.80%	ROI	-	52W High	-53.65%	Beta	-0.09
Dividend %	-	Quick Ratio	29.90	Sales past 5Y	-	Gross Margin	-	52W Low	72.76%	ATR	1.35
Employees	26	Current Ratio	29.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.66	Volatility	5.09% 5.24%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-32.30%	Profit Margin	-	Rel Volume	0.19	Prev Close	24.14
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.30M	Price	23.91
Recom	2.30	SMA20	-5.53%	SMA50	-13.20%	SMA200	-20.71%	Volume	198,651	Change	-0.95%

Nov-16-22

Downgrade

B. Riley Securities

Buy → Neutral

$44

Jul-15-21

Downgrade

Cantor Fitzgerald

Overweight → Neutral

$100

Jul-07-21

Reiterated

Maxim Group

Buy

$80 → $190

Apr-27-21

Initiated

B. Riley Securities

Buy

$78

Feb-16-21

Reiterated

H.C. Wainwright

Buy

$20 → $66

Oct-23-20

Initiated

Cantor Fitzgerald

Overweight

$24

Sep-23-20

Upgrade

H.C. Wainwright

Neutral → Buy

$20

May-18-20

Downgrade

H.C. Wainwright

Buy → Neutral

May-15-20

Downgrade

Maxim Group

Buy → Hold

Jan-10-20

Reiterated

Maxim Group

Buy

$3 → $12

Mar-09-23 09:45AM	3 Short-Squeeze Stocks to Keep on Your Radar InvestorPlace
Mar-04-23 07:20AM	The three-year returns have been massive for Cassava Sciences (NASDAQ:SAVA) shareholders despite underlying losses increasing Simply Wall St.
Mar-03-23 07:07AM	Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call Thomson Reuters StreetEvents
Feb-28-23 09:15AM	Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates GlobeNewswire
Feb-24-23 01:29PM	3 Drug Stocks to Watch as Alzheimers Clinical Trials End InvestorPlace
09:15AM	Loading…
Feb-08-23 09:15AM	Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimers Disease GlobeNewswire
Feb-01-23 08:55AM	3 Big Reasons to Sell Cassava Sciences Stock Right Now Motley Fool
Jan-25-23 08:27PM	Why the Dip in Cassava Sciences (SAVA) Stock Shouldnt Spook You TipRanks -6.62%
Jan-24-23 04:06PM	Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors Investor's Business Daily -19.21%
12:22PM	Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results Benzinga
09:15AM	Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimers Disease GlobeNewswire
Jan-18-23 10:35AM	Cassava Sciences Stock Shows Big Jump In Its Relative Strength Rating Investor's Business Daily
Jan-12-23 09:40AM	Is Mesa Laboratories (MLAB) Outperforming Other Medical Stocks This Year? Zacks
Jan-03-23 09:16AM	Cassava Sciences, Inc. (NASDAQ:SAVA) most popular amongst individual investors who own 69% of the shares, institutions hold 25% Simply Wall St. -6.03%
Dec-20-22 09:15AM	Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD GlobeNewswire
09:15AM	Loading…
Dec-06-22 09:15AM	Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimers Disease GlobeNewswire
Nov-22-22 12:30PM	Cassava Sciences Announces Closing of $50 Million Registered Direct Offering GlobeNewswire
Nov-18-22 01:30PM	Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock GlobeNewswire
Nov-16-22 10:43AM	7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022 InvestorPlace -13.04%
Nov-15-22 10:00AM	Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy Study Benzinga
Nov-14-22 03:54PM	Cassava Sciences stock pops after rival experiences setback in Alzheimers research Yahoo Finance Video +9.44%
Nov-07-22 09:00AM	Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates GlobeNewswire
06:15AM	What the Latest Controversy Really Means for SAVA Stock InvestorPlace
Nov-04-22 10:49AM	Short sellers hit back at Cassava lawsuit against them: We stand behind everything we wrote MarketWatch
Nov-03-22 09:15AM	Cassava Sciences Files Lawsuit Against Perpetrators of Short and Distort Campaign GlobeNewswire
Nov-01-22 02:21PM	Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store? Zacks
Oct-31-22 05:50PM	Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know Zacks
06:15AM	A New Study Makes Cassava Sciences Stock an Interesting Buy InvestorPlace
Oct-27-22 09:15AM	Cassava Sciences Announces Expansion of Leadership Team GlobeNewswire
Oct-25-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know Zacks
05:50PM	Loading…
Oct-17-22 05:50PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Oct-13-22 09:15AM	Cassava Sciences Announces Initiation of an Open-label Extension Study GlobeNewswire
Oct-11-22 06:00PM	Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know Zacks
06:00AM	Dont Let Misconduct Allegations Cloud Your Perception of SAVA Stock InvestorPlace
Oct-05-22 06:15AM	2 Signals to Watch Before Buying SAVA Stock InvestorPlace
Sep-30-22 10:35AM	How High Can SAVA Stock Go Once the Controversy Clears? InvestorPlace
Sep-29-22 06:15PM	Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know Zacks
Sep-27-22 01:11PM	Caution! Its Not Safe to Jump on the SAVA Stock Hype Train. InvestorPlace
Sep-23-22 04:11PM	Cassava Plummets After Refuting New Claims Around Data Tampering Investigation Investor's Business Daily -18.00%
01:43PM	Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating Investor's Business Daily
09:19AM	10 Most Shorted Stocks in September Insider Monkey
Sep-16-22 06:15PM	Cassava Sciences, Inc. (SAVA) Dips More Than Broader Markets: What You Should Know Zacks
Sep-09-22 12:08PM	16 Best Penny Stocks to Buy Now Insider Monkey +10.77%
Sep-08-22 09:15AM	Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-05-22 08:01PM	Strong Insider Buying Makes These 2 Stocks Attractive TipRanks
Aug-18-22 01:06PM	Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims Benzinga
09:15AM	No Evidence of Data Manipulation in Science Publication on Simufilam GlobeNewswire
Aug-17-22 01:40PM	Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning Motley Fool +27.26%
Aug-16-22 06:09PM	Top after-hours movers: Apple, Cassava Sciences, Canoo, Digital World Acquisition Corp. Yahoo Finance
05:10PM	Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo Yahoo Finance Video
Aug-03-22 09:15AM	Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study GlobeNewswire
Jul-29-22 01:29PM	10 Stocks to Sell Before They Die InvestorPlace
Jul-27-22 02:58PM	Cassava's stock dives 21% after report citing alleged criminal probe of data from Alzheimer's drug trial MarketWatch -13.95%
01:36PM	Cassava Sciences Responds to Media Reports GlobeNewswire
10:08AM	We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate Simply Wall St.
07:10AM	Cassava Sciences Shares Plunge After Criminal Investigation Report Benzinga
06:05AM	Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say Reuters
Jul-26-22 06:15PM	Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know Zacks
Jul-24-22 10:00AM	7 Meme Stocks Trading at a Massive Discount Right Now InvestorPlace
Jun-24-22 06:15PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Jun-16-22 06:15PM	Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know Zacks
May-25-22 11:32AM	The 7 Best Meme Stocks to Buy Now InvestorPlace +6.30%
May-05-22 09:00AM	Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program GlobeNewswire
May-04-22 08:48AM	Cassava Sciences May Be Heading Below $10 Per Share InvestorPlace
Apr-29-22 02:40PM	Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms InvestorPlace
Apr-28-22 05:50PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Apr-26-22 03:03PM	Take Full Advantage of Weakness in Cassava Sciences Stock InvestorPlace
Apr-25-22 03:11PM	Cassava Sciences Is a Worthwhile Bet to Consider InvestorPlace +8.42%
09:00AM	Cassava Sciences Invited to Participate in B. Riley Securities Neuroscience Conference GlobeNewswire
Apr-19-22 03:17PM	Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait Simply Wall St. -11.26%
Apr-15-22 09:30AM	10 Meme Stocks Redditors are Buying in April Insider Monkey
Apr-14-22 07:14PM	Top Sports Betting Stocks for Q2 2022 Investopedia
Apr-11-22 05:04PM	Cassava Sciences Is Worth Considering After Hitting Its Latest Trough InvestorPlace
03:49PM	Is There An Opportunity With Boyd Gaming Corporation's (NYSE:BYD) 41% Undervaluation? Simply Wall St.
Apr-08-22 08:59AM	Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm Zacks
Apr-07-22 05:29PM	Cassava Stock: Despite Overhangs, the Risk-Reward Looks Appealing, Says Analyst TipRanks
Apr-06-22 06:11PM	Top 10 Stocks Billionaire David Einhorn Just Added to His Portfolio Insider Monkey -6.50%
Apr-04-22 06:00PM	Cassava Sciences, Inc. (SAVA) Outpaces Stock Market Gains: What You Should Know Zacks
09:00AM	Webcast Details for Cassava Sciences Upcoming Fireside Chat GlobeNewswire
Apr-01-22 11:37AM	Here's Why Cassava Sciences Stock Could Make a Comeback Motley Fool
Mar-30-22 06:18PM	Risk-on Biotech Investors Should Buy Cassava Sciences InvestorPlace
09:00AM	Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th GlobeNewswire
Mar-25-22 06:00PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Mar-18-22 05:50PM	Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know Zacks
Mar-15-22 01:33PM	Keep Risk in Mind With Cassava Sciences Stock, but Dont Dismiss Upside Potential InvestorPlace +6.90%
Mar-10-22 06:00PM	Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know Zacks
Mar-04-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know Zacks
08:48AM	Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options Zacks
Mar-03-22 04:45PM	Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days InvestorPlace -8.64%
Mar-01-22 04:41PM	Cassava: Making Big Things Happen? This 5-Star Analyst Thinks So TipRanks -5.50%
Feb-28-22 04:03PM	Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates GlobeNewswire
Feb-25-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know Zacks
01:17PM	Why Cassava Sciences Is Still a High-Risk Play InvestorPlace
Feb-18-22 03:01PM	10 Most Shorted Stocks Right Now Insider Monkey
Feb-17-22 01:35PM	We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely Simply Wall St. -7.77%
Feb-15-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know Zacks
Feb-11-22 10:53AM	This Analyst Goes Back to the Future to Recommend Cassava Stock TipRanks
Feb-10-22 04:07PM	FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients GlobeNewswire +7.78%
Feb-08-22 05:50PM	Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know Zacks
05:30PM	Does Cassava Sciences and Its Alzheimers Drug Really Have What It Takes? InvestorPlace

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O DONNELL MICHAEL J	Director	Mar 07	Option Exercise	18.13	7,142	129,484	12,012	Mar 08 04:12 PM
Barry Richard	Director	Mar 07	Buy	25.76	77,276	1,990,630	275,000	Mar 08 04:07 PM
Barry Richard	Director	Mar 06	Buy	26.13	11,565	302,193	197,724	Mar 08 04:07 PM
FRIEDMANN NADAV	Chief Medical Officer	Oct 03	Option Exercise	0.95	9,376	8,907	79,910	Oct 03 06:01 PM
ROBERTSON SANFORD	Director	Sep 08	Option Exercise	23.59	2,802	66,099	1,027,567	Sep 12 04:00 PM
Barry Richard	Director	Aug 23	Buy	23.79	36,159	860,223	186,159	Aug 25 04:20 PM
Kupiec James William	Chief Clinical Dev. Officer	Aug 23	Buy	24.44	2,500	61,100	2,500	Aug 24 04:02 PM
ROBERTSON SANFORD	Director	Aug 12	Buy	20.69	100,000	2,069,000	1,024,765	Aug 16 04:24 PM
Schoen Eric	Chief Financial Officer	Aug 12	Buy	19.95	2,500	49,875	19,800	Aug 16 04:28 PM
BARBIER REMI	President and CEO	Jun 06	Option Exercise	23.38	65,368	1,528,304	822,437	Jun 07 06:24 PM
FRIEDMANN NADAV	Chief Medical Officer	May 27	Option Exercise	23.38	28,014	654,967	95,103	May 31 04:20 PM
BARBIER REMI	President and CEO	Apr 25	Option Exercise	2.40	49,460	118,703	376,112	Apr 25 06:29 PM
GUSSIN ROBERT Z	Director	Mar 29	Option Exercise	21.53	7,470	160,856	12,434	Mar 29 07:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience